Bone metabolism in 2012: Novel osteoporosis targets

Researchers are trying to develop more efficient and safer antifracture treatments. Besides the ongoing promising clinical trials involving antibodies to the Wnt antagonist sclerostin or inhibition of the osteoclast enzyme cathepsin K, the year 2012 has seen several novel osteoporosis targets identified by using different methodological approaches.

[1]  M. Zaidi,et al.  Translational medicine: Double protection for weakened bones , 2012, Nature.

[2]  M. Blaser,et al.  Antibiotics in early life alter the murine colonic microbiome and adiposity , 2012, Nature.

[3]  R. Knight,et al.  Evolution of Mammals and Their Gut Microbes , 2008, Science.

[4]  T. Spector,et al.  Risk of Wrist Fracture in Women Is Heritable and Is Influenced by Genes That Are Largely Independent of Those Influencing BMD , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  David M. Evans,et al.  WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk , 2012, PLoS genetics.

[6]  T. Kodama,et al.  Osteoprotection by semaphorin 3A , 2012, Nature.

[7]  A. Uitterlinden,et al.  Genetics of osteoporosis , 2007, Proceedings of the Nutrition Society.

[8]  J. Reginster,et al.  Fracture risk and zoledronic acid therapy in men with osteoporosis. , 2012, The New England journal of medicine.

[9]  V. Tremaroli,et al.  The gut microbiota regulates bone mass in mice , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  Daniel L. Koller,et al.  Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture , 2012, Nature Genetics.